The hottest Cancer Research Substack posts right now

Ivermectin and other generic drugs are being explored for cancer treatment by medical pioneers.
Physicians are attempting to make cancer care more effective, affordable, and less painful using safe, off-patent drugs.
Generic drugs like ivermectin and mebendazole are showing promise in inhibiting cancer cell growth and inducing cell death in various cancer types.

Teaching Black History Month to kids through a Black Lives Matter coloring book has sparked controversy and concerns among parents regarding the content being taught in schools.
The importance of teaching actual black history, like the stories of the Tuskegee Airmen, as opposed to contemporary political ideologies in schools.
The issue of fraud in cancer research highlights the lack of transparency in data sharing within the scientific community, leading to questions about the integrity of medical research and the need for more stringent protocols.

Doctors who run unethical clinical trials often get praised and promoted.
The design of clinical trials must ensure the control arm receives the best available care, not inferior treatment.
Rewarding unethical trials in oncology sets a dangerous precedent and can harm patients.

Developing drugs that target pathways triggered by pathogens can lead to faster, more effective treatments for various diseases, even when the specific pathogen is unknown.
mRNA vaccines are faster, cheaper, and more flexible to make than traditional vaccines, offering a promising future in preventing infections and addressing persistent pathogens like herpes.
mRNA vaccines have the potential to be used as personalized cancer vaccines by instructing the body's cells to create proteins that trigger an immune response against cancer cells, showing great promise in cancer treatment and immunotherapy.

Destroying tumors while sparing healthy tissue is a key challenge in cancer research.
Radioisotopes show promising potential in selectively attacking tumors.
The radiopharmaceutical space, though historically lagging, is now gaining traction with new developments and interest from large pharmaceutical companies.

Get a weekly roundup of the best Substack posts, by hacker news affinity: